CL2017001008A1 - Uso de una composicion de vacuna de hpv para tratar cancer y lesion de la piel. - Google Patents
Uso de una composicion de vacuna de hpv para tratar cancer y lesion de la piel.Info
- Publication number
- CL2017001008A1 CL2017001008A1 CL2017001008A CL2017001008A CL2017001008A1 CL 2017001008 A1 CL2017001008 A1 CL 2017001008A1 CL 2017001008 A CL2017001008 A CL 2017001008A CL 2017001008 A CL2017001008 A CL 2017001008A CL 2017001008 A1 CL2017001008 A1 CL 2017001008A1
- Authority
- CL
- Chile
- Prior art keywords
- carcinoma
- vaccine composition
- treat cancer
- skin lesion
- hpv vaccine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 206010040882 skin lesion Diseases 0.000 title 1
- 231100000444 skin lesion Toxicity 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 abstract 5
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001008A1 true CL2017001008A1 (es) | 2017-11-24 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001008A CL2017001008A1 (es) | 2014-10-24 | 2017-04-24 | Uso de una composicion de vacuna de hpv para tratar cancer y lesion de la piel. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (enExample) |
| EP (1) | EP3209676A4 (enExample) |
| JP (1) | JP6663438B2 (enExample) |
| KR (1) | KR102285401B1 (enExample) |
| CN (1) | CN107001430A (enExample) |
| AU (1) | AU2015335652B2 (enExample) |
| BR (1) | BR112017008280A2 (enExample) |
| CA (1) | CA2965498A1 (enExample) |
| CL (1) | CL2017001008A1 (enExample) |
| IL (1) | IL251825B2 (enExample) |
| MX (1) | MX395186B (enExample) |
| MY (1) | MY195018A (enExample) |
| PH (1) | PH12017500754A1 (enExample) |
| SG (1) | SG11201703262UA (enExample) |
| WO (1) | WO2016065281A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019506435A (ja) * | 2016-02-27 | 2019-03-07 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60126737T2 (de) * | 2001-03-23 | 2007-11-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| TWI349557B (en) | 2002-12-20 | 2011-10-01 | Glaxosmithkline Biolog Sa | Use of hpv 16 and hpv 18 vlps for vaccine preparation |
| PE20060434A1 (es) * | 2004-06-16 | 2006-06-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| CN101622008A (zh) * | 2007-03-09 | 2010-01-06 | 默克公司 | 乳头瘤病毒疫苗组合物 |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| EP2416798B1 (en) * | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| US9724404B2 (en) * | 2009-04-13 | 2017-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | HPV particles and uses thereof |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| US9566323B2 (en) | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| BRPI1014718A2 (pt) * | 2009-06-25 | 2016-04-12 | Glaxonsmithkline Biolog S A | polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| CA2838387A1 (en) * | 2011-06-06 | 2012-12-13 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| BR112014023092A8 (pt) * | 2012-03-18 | 2017-07-25 | Glaxosmithkline Biologicals Sa | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit |
| WO2013149017A1 (en) * | 2012-03-28 | 2013-10-03 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
-
2017
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001430A (zh) | 2017-08-01 |
| MY195018A (en) | 2023-01-03 |
| JP6663438B2 (ja) | 2020-03-11 |
| MX2017005418A (es) | 2017-11-30 |
| IL251825B2 (en) | 2023-09-01 |
| EP3209676A1 (en) | 2017-08-30 |
| KR102285401B1 (ko) | 2021-08-02 |
| US20160114023A1 (en) | 2016-04-28 |
| SG11201703262UA (en) | 2017-05-30 |
| US10238729B2 (en) | 2019-03-26 |
| WO2016065281A1 (en) | 2016-04-28 |
| CA2965498A1 (en) | 2016-04-28 |
| JP2017531699A (ja) | 2017-10-26 |
| BR112017008280A2 (pt) | 2018-01-02 |
| IL251825A0 (en) | 2017-06-29 |
| EP3209676A4 (en) | 2018-03-28 |
| PH12017500754A1 (en) | 2017-10-30 |
| AU2015335652A1 (en) | 2017-05-25 |
| KR20170072279A (ko) | 2017-06-26 |
| AU2015335652B2 (en) | 2020-07-02 |
| MX395186B (es) | 2025-03-21 |
| IL251825B1 (en) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
| CL2018000515A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015) | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| PH12017500803A1 (en) | Anti-pd-1 antibodies | |
| MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX391083B (es) | Uso de alfavirus en preparaciones de fármacos antitumorales. | |
| MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
| MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
| IN2014MU00303A (enExample) | ||
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2018013340A (es) | Combinaciones de vacunas terapeuticas para el vph. | |
| SG11202103097QA (en) | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| CL2018002438A1 (es) | Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. | |
| CL2017001008A1 (es) | Uso de una composicion de vacuna de hpv para tratar cancer y lesion de la piel. | |
| AR110679A1 (es) | Linfocitos infiltrantes remanentes de tumor y métodos de preparación y usos de los mismos |